All posts by Ciara Jackson

Aptar Pharma and Nanopharm Featured in ONdrugDelivery’s Novembe...

Aptar Pharma is featured in the November 2019 edition of ONdrugDelivery magazine, which focuses on Pulmonary & Nasal Drug Delivery.

In this interesting article entitled “A Faster, More Cost-Effective Alternative to Generic Bioequivalence”, Dr. Jag Shur, CEO of Nanopharm, an Aptar Pharma company, explores the challenges companies face in bringing generic respiratory and nasal therapies to market amidst a changing regulatory landscape.  He explains the Aptar Pharma Services range for accelerating and derisking OINDP development, and introduces the CPhI 2019 Award winning SmartTrack as an alternative to bioequivalence studies.

Read the full article here.

 

November 27, 2019

Aptar Pharma Experts to Host Webinar on Analytical Strategies for...

Aptar Pharma will host a live educational webinar entitled “Breathe Easy: Selecting analytical strategies for inhaled drug product development” on Thursday, December 5, 2019 at 3.30 pm GMT/10.30 am ET.

Led by OINDP experts from Next Breath and Nanopharm, both Aptar Pharma companies, this webinar will examine the analytical methods and regulatory frameworks associated with ensuring and establishing bioequivalence. It will question which analytical methods are most relevant to OINDP in vitro bioequivalence studies, as well as explore what supporting evidence can be generated to aid formulation optimization, therefore helping to expedite successful product development and regulatory submission.

This webinar, which is sponsored by Malvern Panalytical and is free to attend, will be co-presented by Dr. Julie D. Suman, Founder & President, Next Breath and Dr. Jag Shur, CEO, Nanopharm.

The webinar will be available on-demand after the live presentation.

Click here to register: https://bit.ly/2O8CIIN.

 

 

November 26, 2019

Aptar Pharma Platinum Sponsor at DDL 2019 to Showcase Expanded Po...

Aptar Pharma is pleased to announce its Platinum Sponsorship of this year’s Drug Delivery to the Lung (DDL) Conference 2019, which takes place from December 11-13 in Edinburgh, Scotland.

Aptar Pharma will exhibit its broad respiratory portfolio and showcase its latest drug delivery innovations and services for respiratory devices at the three-day conference, which is celebrating its 30th anniversary this year.

A worldwide leader in respiratory drug delivery devices for the treatment of asthma and COPD, Aptar Pharma will exhibit at Booth 432 at DDL, where their team of experts will showcase their innovative range of respiratory drug delivery systems and connected devices that help improve adherence and patient health outcomes.

Noble International, a global leader in drug delivery device trainers and patient onboarding and the latest addition to the Aptar Pharma family, will also be on exhibit at Booth 432.

Also exhibiting at Booth 432 will be Aptar CSP Technologies, the active packaging specialists.

Aptar Pharma’s newly expanded Aptar Pharma Services platform will also be highlighted at DDL 2019. Leading experts from Aptar Pharma companies Nanopharm, Next Breath and Gateway Analytical will be on hand at the following Booths to discuss how their value-added services can help customers accelerate and derisk their drug development journey:

Nanopharm will exhibit at Booth 518
Next Breath will exhibit at Booth 516
Gateway Analytical will exhibit at Booth 514.

To further share its expertise in respiratory drug delivery with the scientific community, Aptar Pharma will be presenting five scientific posters, during DDL 2019. Delegates and attendees will have the opportunity to view them during the dedicated poster sessions, which will take place daily at the Conference.

Guillaume Brouet, Vice-President Regulatory, Analytical & Scientific Affairs at Aptar Pharma, commented, “As a leader in inhalation drug delivery systems, we are proud to be a Platinum Sponsor of DDL this year. We look forward to showcasing our expanded Aptar Pharma device, technologies and services offering, which provide complete solutions for customers and further support their respiratory drug development journeys”.

Aptar Pharma is also a sponsor of the special DDL 2019 Dinner celebrating DDL’s 30th Anniversary, which will take place on Thursday, December 12th and to which all delegates and exhibitors are invited.

Download full Press Release here.

November 25, 2019

Aptar Pharma’s Preservative-Free Multidose Dispenser Approved i...

Aptar Pharma is pleased to announce that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH® RELIEVA™ PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S.

This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives for prescription and OTC products.

Launched along with REFRESH® RELIEVA™ PF are REFRESH® RELIEVA™ and REFRESH® RELIEVA™ FOR CONTACTS. This new line of artificial tear formulations from Allergan is specifically developed to relieve discomfort due to eye dryness and to prevent further irritation. REFRESH®, a doctor recommended brand for artificial tears, further expands its portfolio by offering the only family of products in the U.S. with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), glycerin, and Allergan’s HydroCell™ technology. This formulation enables hydration and maintains the volume of cells on the ocular surface.

Preservatives have been known to cause signs and symptoms of irritation, allergy and ocular surface toxicity. Aptar Pharma has been partnering with Allergan across numerous preservative-free product launches.

“Our Ophthalmic Squeeze Dispenser technology has been launched with close to 250 preservative free eye care products worldwide. Its proven unrivalled microbiological safety combined with a diverse technological platform enables our customers to introduce their formulations to market in the purest form and offering outstanding convenience, meeting the needs of consumers and patients,” explained Matthias Birkhoff, VP Business Development, Aptar Pharma. “By offering the first and only FDA-reviewed technology for multidose preservative-free systems, our customers can rely on Aptar Pharma’s comprehensive service package to support their development of eye care products without preservatives.”

Allergan is a leader in eye care, with 70 years of experience and over 125 eye care products launched, among those some of the most innovative products in the industry.

Download Full Press Release here.

 

Photo: Courtesy of Allergan

November 22, 2019

Aptar Pharma’s Nanopharm Wins "Excellence in Pharma" Award for ...

Aptar Pharma announces that Nanopharm has won an Excellence in Pharma Award at the 2019 CPhI Pharma Awards. Nanopharm, an Aptar Pharma company and part of our expanded services offering, won in the Contract Services and Outsourcing category for its recently-launched SmartTrack™ process.

Accepting the award were Dr. Jag Shur, CEO of Nanopharm, and Guillaume Brouet, Vice-President of Analytical, Regulatory and Scientific Affairs at Aptar Pharma.

The award was presented as part of the 16th annual CPhI Pharma Awards dinner, which took place Tuesday, November 5th at the Forum at Messe Frankfurt, Germany.

Established in 2004, the CPhI Pharma Awards are one of the most prestigious recognition’s in the Pharmaceutical industry today, and celebrate the innovation and dedication of companies and individuals who are driving the pharmaceutical industry forward. This year’s awards included 13 categories that span the entire industry’s supply chain.

A specialist in respiratory drug delivery services, Nanopharm is the world’s leading contract provider of orally inhaled and nasal drug product (OINDP) design and formulation development services to customers worldwide. Recognized for their advanced scientific understanding, Nanopharm offers an integrated solution approach via SmartTrack™.

SmartTrack™ is a novel integrated solution providing an alternative bioequivalence (BE) clinical endpoint approach. SmartTrack™ can dramatically decrease program costs, mitigate risk and expedite development from concept to delivery, ensuring that every aspect of a drug product development’s critical path is optimized.

“This award marks a significant milestone for our SmartTrack™ platform, and signifies the R&D endeavor at Nanopharm to develop alternative bioequivalence strategies for OINDPs,” commented Jag Shur, PhD, Chief Executive Officer of Nanopharm. “I would like to thank our employees, clients and partners in this success.”

Aptar Pharma President Gael Touya, who was on hand to present the Excellence in Pharma Drug Delivery Device and Packaging Awards at this year’s event added, “We are delighted that Nanopharm’s SmartTrack™ was recognized by the industry for its innovative approach. This reinforces the Aptar Pharma Services mission to further help customers during their entire product lifecycle of the drug product and deliver them a complete solution.”

Aptar Pharma, along with Nanopharm, are a main exhibitor at CPhI Worldwide 2019, which is taking place in Frankfurt, Germany from November 5 – 7. For several years, Aptar Pharma has had a significant presence at this major event in the pharmaceutical industry attended by over 45,000 Pharma professionals.

Download the press release here.

 

 

November 6, 2019

Aptar Pharma to Showcase Latest Injectables Offerings at PDA PFS,...

Aptar Pharma is pleased to be exhibiting at 2019 PDA Universe of Pre-Filled Syringes and Injection Devices (PDA PFS), taking place October 22-23 in Gothenburg, Sweden.

At Booth No. F72, we will be showcasing our broad PFS product portfolio including the latest developments in our Premium injectables offering: PremiumFill®, PremiumCoat™ and PremiumVision™.

Learn more about our newly expanded Aptar Pharma Service Platform. Meet with experts from Aptar Pharma’s analytical services company, Gateway Analytical, who will be on hand to discuss how their value-added services can help customers accelerate and derisk their drug development journey.

Visitors to our booth can find out how Aptar Pharma is driving for supply chain excellence by increasing production capabilities and capacity worldwide.

A scientific poster entitled “Evaluating the impact of Sterilization Methods on Stopper Performances” – a collaborative study by Aptar Pharma and BD Medical – will also be presented during the poster sessions on both days of PDA PFS 2019.

PDA PFS has been running since 2004 and has become a must-attend event for those working in the biopharmaceutical and parenteral drug delivery and device development fields. This is the first time the event will be held in Gothenburg. Aptar Pharma looks forward to welcoming you there!

For more information on PDA PFS 2019, click here.

October 15, 2019

Aptar Pharma to Highlight Expanded Services Platform at CPhI Worl...

Aptar Pharma is pleased to be an exhibitor once again at CPhI Worldwide 2019, which will take place November 5-7 in Frankfurt, Germany.

At Stand 111D70, Aptar Pharma will showcase its diverse portfolio of drug delivery systems, components and active packaging solutions including their latest innovations across nasal, pulmonary, eye care, injectables and dermal drug delivery routes. These innovations will include:

  • PureHale – a revolutionary, portable and ready-to-use device designed to deliver natural care to upper airways
  • QuickStartTM for Injectables – a sterile, ready-to-use early stage injectable development package now orderable on aptar.com/pharma
  • Nanopharm’s SmartTrackTM – a novel approach to decrease program costs and avoid BE studies in OINDPs

A dedicated Connectivity hub hosting their range of connected drug delivery devices will demonstrate Aptar Pharma’s focus on building a connected devices eco-system for digital medicines.

Aptar Pharma’s newly expanded Aptar Pharma Services platform will be introduced at this year’s CPhI WW.  Offering early stage to commercialization services, Aptar Pharma has over 25 years’ experience supporting regulatory submissions. Leading experts from Aptar Pharma’s analytical services companies Nanopharm, Next Breath and Gateway Analytical will be on hand to discuss how their value-added services can help customers accelerate and derisk their drug development journey.

Aptar CSP Technologies, part of the Aptar family, will be presenting their extensive portfolio of active packaging solutions including the award-winning XcelerateTM Development Services which can help expedite time-to-market for moisture- and oxygen-sensitive drugs.

On Wednesday, November 6, Aptar Pharma will present three free-to-attend Pharma Insight Briefings:

  • “Driving Foreign Particulate Analysis: How to Choose Between Manual and Automated,” presented by David Exline, President, Gateway Analytical, an Aptar Pharma company
  • “Advantages of Nasal Powders for Drug Repurposing,” presented by Dr Gerallt Williams, Director Scientific Affairs, Aptar Pharma
  • “Beyond Pharmaceutical Packaging: New Solutions to Old Challenges,” presented by Badre Hammond, Vice-President, Commercial Operations, Aptar CSP Technologies.

CPhI Worldwide, the world’s largest pharmaceutical exhibition, is celebrating its 30th anniversary this year and expects to welcome more than 45,000 visitors and 2,500 international exhibitors.

Download the full press release.

October 6, 2019

Aptar Pharma’s Nasal Unidose Device Approved for Tosymra™ Sum...

Aptar Pharma, a leading provider of drug delivery devices worldwide today announced that its patented Unidose Liquid System is the device which delivers Tosymra™ (sumatriptan) Nasal Spray 10mg, for the acute treatment of migraine in adults.

Now available in the U.S., Tosymra was approved by the U.S. Food and Drug Administration (FDA) in January 2019 and is being commercialized by Upsher-Smith Laboratories, LLC.

For migraine sufferers, there is a continued need for reliable and efficacious treatment options. Tosymra nasal spray is formulated using a proprietary excipient to achieve blood levels similar to a 4-mg sumatriptan subcutaneous injection. Aptar’s Unidose device delivers one dose of Tosymra as a single spray providing a convenient, patient-friendly delivery approach.

This approval and launch again demonstrates Aptar Pharma’s expertise in developing patient-friendly drug delivery solutions for medicines. Aptar offers a broad portfolio of innovative technologies and wide array of services to meet the highest quality standards of the pharmaceutical industry.

This migraine treatment is an example of a Combination Product submission, and benefited from Aptar Pharma’s Services offering, a comprehensive portfolio of stage-specific development packages. Aptar’s dedicated Regulatory Affairs experts and analytical scientists help customers proactively address regulatory needs to obtain approval.

“We are pleased that Aptar Pharma’s Unidose System has once again been approved by the FDA and launched with an important new nasal treatment for acute treatment of migraine that provides a patient-friendly delivery approach,” commented Gael Touya, President, Aptar Pharma. “Our lab and analytic service capabilities combined with our unique drug delivery devices create tremendous value for our customers and help them secure approval. The ultimate end result is that we help expand access to treatments with our life-improving, patient-friendly systems, something for which we are very proud.”

See full Press Release for details.

October 2, 2019

Aptar’s Nasal Unidose Device Approved by US FDA for First Needl...

Crystal Lake, Illinois, July 25, 2019 – AptarGroup, Inc., a global leader in dispensing and drug delivery solutions, today announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

This approval again demonstrates Aptar’s expertise in developing patient-friendly drug delivery solutions for breakthrough medicines. Aptar offers a broad portfolio of innovative technologies and wide array of services to meet the highest quality standards of the pharmaceutical industry.

Solution for Nasally Administered Powder Treatments

Aptar’s Unidose Powder System is a single-use, ready-to-use one-step nasal delivery device which can deliver a powder formulation in an emergency situation quickly and easily. During such an event, the patient or caregiver presses a small plunger on the bottom of the device to release the drug in a single powder puff into the nose, where the drug can be quickly absorbed via the nasal mucosa. Aptar’s Unidose Powder System is an alternative to injectable kits that may require assembly, including a multistep, time-consuming process of mixing powder and liquid.

Patented Unidose and Bidose Technology Platforms

Aptar’s Unidose and Bidose platforms are robust, primeless, and easy-to-use systems with 360° functionality and precise nasal drug delivery. They offer biotech and pharmaceutical companies effective and reliable single or two-shot intranasal delivery for a variety of medicines including potential life-saving drugs and treatments of severe conditions. The devices can also integrate wireless connectivity technologies.

Unidose Device Protected by Aptar’s Integrated Active Packaging Container

This is the first approval and customer launch combining the technologies of Aptar Pharma and Aptar CSP Technologies. The novel container, which protects and stores the Unidose Powder System, was developed by Aptar CSP Technologies, the global material science unit of Aptar, providing innovative, highly engineered advanced active packaging solutions that protect sensitive drug products. The container incorporates Aptar’s three phase Activ-Polymer™ technology which ensures extended moisture protection for the shelf-life of the drug, mitigating the impact of changing environmental conditions associated with temperature and relative humidity.

Accelerated Development Support via Aptar Pharma Services

This innovative therapy in the field of diabetes is an example of a Combination Product submission, and benefited from Aptar Pharma’s Services offering, a comprehensive portfolio of stage-specific development packages. Aptar’s dedicated Regulatory Affairs experts and analytical scientists help customers proactively address regulatory needs to accelerate approval.

“We are pleased to announce that Aptar Pharma’s Unidose Powder System has been approved by the FDA for the first intranasally-delivered, needle-free rescue treatment for severe hypoglycemia that provides a more patient-friendly delivery approach. Our active packaging container helps to protect the device and better ensure its quality until the moment of use,” commented Gael Touya, President, Aptar Pharma. “This project marks a nearly 10-year customer collaboration and once again demonstrates Aptar Pharma’s ability to help our customers develop and launch complex treatments with patient-friendly delivery systems worldwide.”

Stephan Tanda, Aptar’s President and CEO added, “This successful approval confirms the value that we are bringing to our customers in the highly competitive pharmaceutical and biotech industries. With decades of experience in the long-term testing and development phases that are required by regulatory agencies, we are building a stronger solutions platform for the future, and this launch is a glimpse of that future. Our lab and analytic service capabilities combined with our unique drug delivery devices and active packaging solutions create tremendous value for our customers and help them secure approval. The ultimate end result is that we help expand access to life-saving treatments with our patient-friendly systems.”

Download the full Press Release.

 

July 25, 2019

Aptar Pharma Unveils PureHale in Latin America during FCE Pharma ...

Aptar Pharma is pleased to be a key exhibitor at this year’s FCE Pharma exhibition, taking place from May 21-23 at the São Paulo Expo, Sao Paulo, Brazil.

Aptar Pharma has been exhibiting at this key industry event for a number of years and is looking forward to once again sharing our latest innovations at this year’s show.

At Booth No. H021, Hall H, visitors are invited to meet with our drug delivery experts, who will be on hand to present Aptar Pharma’s expanding portfolio of drug delivery solutions and technology innovations across nasal, pulmonary, eye care, dermal and injectable routes.

A highlight of our presence at FCE Pharma 2019 will be the unveiling of Aptar Pharma’s PureHale for the first time in Latin America.  PureHale is a portable and ready-to-use nebulizer-like device, designed to deliver natural care to upper airways.

With growing customer interest in the Latin American market for preservative-free formulations, visitors to the Aptar Pharma booth will have the opportunity to find out more about our Ophthalmic Squeeze Dispense (OSD).  With more than 200 market references worldwide, the Aptar Pharma Ophthalmic Squeeze Dispenser is the first and only FDA approved preservative-free dispensing technology, is suitable for a wide range of viscosities, and was recently approved across Europe for Glaucoma prescription treatment.

FCE Pharma is considered the key annual pharmaceutical and cosmetics tradeshow in Latin America, bringing together all the major players in the pharmaceutical industry to share their knowledge and expertise, exchange ideas and showcase the latest trends and innovations. More than 23,000 visitors are expected to attend this year’s event.

Visit Aptar Pharma at FCE Pharma 2019.  We look forward to welcoming you.

May 17, 2019

Aptar Pharma’s Freepod® Nasal Spray Device with GlaxoSmithKlin...

Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod® nasal spray device with GlaxoSmithKline’s Otrivin® has won a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague.

GlaxoSmithKline’s Otrivin® is well-known globally for providing temporary relief of nasal congestion.  Aptar Pharma’s Freepod®, a multi-dose preservative-free nasal spray pump, with GlaxoSmithKline’s Otrivin® was recognized by the WorldStar Awards jury for its sustainability impact.

Howard Burnett, Aptar Pharma Vice-President Global Account Management, commented, “We congratulate GlaxoSmithKline on this prestigious WorldStar Packaging Award win. At Aptar Pharma, we’re very proud that our patented Freepod® technology has been recognized with GlaxoSmithKline’s Otrivin® as a deserving winner in the Medical & Pharma category of the WorldStar Packaging Award.”

The WorldStar Awards Competition, hosted by the WPO, recognizes the continual advancement and excellence in packaging design and technology, and is considered to be one of the most prestigious international packaging awards events.

Full details found in the Press Release.

 

May 16, 2019

Aptar Pharma to Demonstrate its Expertise in Multi-dose Preservat...

Aptar Pharma, a leading provider of drug delivery systems, services and active packaging solutions worldwide, is pleased to be a key exhibitor at ARVO 2019, taking place on April 28 – May 2 at the Vancouver Convention Center, Vancouver, Canada.

ARVO is an annual international conference, bringing together eye and vision researchers to provide the public, patients and policymakers with insight into how their sight-saving work greatly benefits society.  The theme for ARVO 2019 – ‘From bench to bedside and back’ – will highlight the importance of the full journey that often takes place from research labs to the patient and back to the bench again, in the search for a novel treatment.

Aptar Pharma will exhibit at Booth No. 928, where we will demonstrate our expertise in the field of multi-dose preservative-free packaging for Eye Care to ARVO’s 11,000 expected delegates.

With over 200 references for both prescription medications and consumer products, Aptar Pharma will have a special focus on our Preservative-free multidose Ophthalmic Squeeze Dispenser, which was recently approved for Santen’s prescription treatment for glaucoma in 26 European countries.

Our versatile Ophthalmic Squeeze Dispenser Technology Platform allows for a wide range of configurations and applications, enabling customized solutions for specific ophthalmic formulations. With Aptar Pharma known for creating the first and only FDA-reviewed preservative free dispensing technology, our experts will provide delegates with insight into how we can accelerate customers’ speed-to-market in line with industry standards.

To connect with Aptar Pharma and meet our team of experts, register here for ARVO 2019 today.

 

 

 

April 19, 2019

Aptar Pharma to Exhibit Latest Drug Delivery Innovations at CPhI ...

Aptar Pharma is pleased to be exhibiting at CPhI North America 2019, taking place on April 30–May 2 at McCormick Place in Chicago, Illinois.

At Booth 1721, Aptar Pharma experts will be on hand to present our diverse portfolio of drug delivery systems, services and active packaging solutions, as well as our latest innovations including:

  • Our Bidose nasal drug delivery device, recently approved by the U.S. FDA for a breakthrough treatment of depression
  • Our industry award-winning Aptar Pharma QuickStart™ Injectables – our Ready-to-Use drug development support package designed to accelerate time-to-market for research and development labs
  • Our recently launched PureHale – a portable and ready-to-use device designed to deliver natural care to upper airways

Also, discover Aptar Pharma’s expanded range of connected drug delivery devices, demonstrating our investment in the future of digital medicines, at CPhI North America 2019.  Talk to our experts about our active packaging solutions portfolio from Aptar CSP Technologies, now part of the Aptar family, helping to optimize your drug product’s packaging environment.

Find out how Aptar Pharma is expanding its North America manufacturing to be closer to customers.  Equipped with the latest technologies to meet growing quality requirements for regulated markets, our recently expanded capabilities at our Congers, NY site will continue to deliver solutions to our customers’ drug delivery challenges.

CPhI North America expects to welcome more than 6,500 industry professionals this year.  During this three-day event, leaders from across the pharma supply chain will gather to exchange ideas, build partnerships and shape the future of the field.

To register for this event, please click here.

April 18, 2019

Aptar Pharma’s Global Services Offering Featured in ONdrugDeliv...

Aptar Pharma is featured in the April 2019 edition of ONdrugDelivery magazine, which focuses this month on Pulmonary & Nasal Drug Delivery.

In this in-depth interview, Aptar Pharma’s Guillaume Brouet, Vice-President Analytical, Regulatory and Scientific Affairs, discusses Aptar Pharma’s comprehensive range of services available to customers around device development, the importance of offering services with a patient-centric approach, and Aptar’s proven expertise in regulatory and combination product approvals.

Read the full article here.

April 11, 2019

Aptar Pharma Co-Organizer and Diamond Sponsor of RDD Europe 2019 ...

Aptar Pharma, the leader in respiratory drug delivery systems, is proud to announce its co-organization and diamond sponsorship of the Respiratory Drug Delivery (RDD®) Europe 2019 scientific conference, connecting pulmonary and nasal drug delivery experts from around the world in Estoril, Portugal from May 7-10, 2019.

 One of the largest respiratory health conferences worldwide, RDD Europe 2019 is a premium, interactive three-day conference offering a prestigious program that includes a plenary lecture and seven plenary sessions hosted by industry experts – including a U.S. FDA speaker – who will share their perspectives and latest accomplishments in pulmonary and nasal drug delivery. This international symposium also offers delegates the latest insights into issues facing the global inhalation community, and numerous business networking opportunities.

As part of their Diamond Sponsorship, Aptar Pharma will lead three interactive workshops dedicated to connected health.  Entitled “The Future of Connected Medicines: Promise and Potential Pitfalls”, these sessions will take place on Wednesday, May 8 and will be presented by Sai Shankar Director, Business Development – Connected Devices at Aptar Pharma along with David Van Sickle, Co-founder and CEO at Propeller Health.

Reaffirming their respiratory expertise, Aptar Pharma will also present two scientific posters during RDD Europe 2019, co-presented by Dr. Gerallt Williams, Director Scientific Affairs, Aptar Pharma:

  • “Human Factor studies for unit-dose nasal sprays – a case study”, co-presented by Williams, B. Grosjean, D. Chopard, P. Schwartz, J. Cabiddu
  • “Investigation of leachables from pMDIs containing HFA 152a”, co-presented by Sarrailh, A. Piquenot, O. Michelet, G. Williams.

In addition to co-organizing the conference, Aptar Pharma will showcase their extensive portfolio of MDIs, DPIs and BAIs, including the growing range of connected devices, at an interactive Exhibit Table. Available as either add-on or fully integrated, Aptar’s c-devices can deliver improved patient health outcomes through better adherence. Also, discover the portfolio of active packaging solutions from Aptar CSP Technologies, now part of the Aptar family, which can help optimize your drug product’s packaging environment.

As Platinum Sponsor, Aptar Pharma will be hosting the Gala Dinner at RDD Europe 2019, which will take place on Thursday May 9 at Sud Lisboa, located on the banks of the Tagus River in Lisbon. Gael Touya, President of Aptar Pharma, will be on hand to welcome guests to this much-anticipated event, which combines fine-cuisine, dancing and networking to cap off the conference.

Register today at https://www.rddonline.com/rddeurope2019  for RDD Europe 2019 – a must-attend conference for companies involved in research, development, testing and marketing of medicines, as well as devices and services associated with pulmonary or nasal products.

See full Press Release for details.

 

 

March 21, 2019

Aptar Pharma to Showcase New Market Innovations at Interphex 2019...

Aptar Pharma, a leading drug delivery systems provider, is pleased to be exhibiting at Interphex 2019, taking place April 2-4 at the Javits Center in New York City.

Located at Booth 1734, Aptar Pharma experts will be on hand to present our diverse portfolio of drug delivery systems, components, services and active packaging solutions, including our latest innovations across nasal, pulmonary, eye care, injectables and dermal drug delivery routes including our:

  • Bidose nasal drug delivery device, recently approved by the U.S. FDA for a breakthrough treatment of depression
  • Industry award-winning Aptar Pharma QuickStart™ Injectables – our Ready-to-Use drug development support package designed to accelerate time-to-market for research and development labs
  • Recently-launched PureHale – a portable and ready-to-use device designed to deliver natural care to upper airways
  • Expanded range of connected drug delivery devices, showing how Aptar Pharma is investing in the future of digital medicines
  • Active packaging solutions portfolio from Aptar CSP Technologies, now part of the Aptar family, which help optimize your drug product’s packaging environment.

Furthermore, Aptar Pharma will highlight our expanded state-of-the-art manufacturing facility in North America. Equipped with the latest technologies to meet growing quality requirements for regulated markets, find out how we have expanded our capabilities at our Congers, NY site to continue to deliver solutions to our customers’ drug delivery challenges.

Aptar Pharma’s PureHale will also be featured in a Technical Theater & Workshop session at Interphex 2019. Entitled “Portable care for your respiratory tract: Exploring new technology platforms”, this workshop will take place on April 3 at 4:00pm and will be presented by Aileen Power, Account Manager – Aptar Pharma Consumer Health Care division.

Interphex is a premier pharmaceutical, biotechnology and device development and manufacturing event, bringing over 11,000 global industry professionals and 650+ leading suppliers together to leverage quality, efficiency and cost effectiveness in today’s ever-changing global market.

To register to attend Interphex 2019, please click here.

March 21, 2019

Aptar Pharma’s Bidose Nasal Drug Delivery Device Approved by U....

Aptar Pharma, a leading drug delivery systems provider, is pleased to announce that its Bidose nasal spray device was recently approved by the U.S. FDA for a breakthrough therapy in the field of depression. This marks the first FDA approval and U.S. launch of a prescription drug using Aptar Pharma’s patented Bidose nasal spray delivery system.

This approval again demonstrates Aptar Pharma’s expertise in developing patient-friendly drug delivery solutions for breakthrough medicines. Aptar Pharma offers a broad portfolio of innovative technologies and a wide array of services to meet the highest quality standards of the pharmaceutical industry.

Designed for local or systemic delivery of drugs, Aptar Pharma’s Bidose liquid system is a robust, primeless, intuitive and easy-to-use device with 360° functionality and precise spray characteristics and provides accurate two-shot nasal drug delivery.

This customized Bidose liquid device is produced in Aptar Pharma’s state-of-the-art manufacturing facility in Congers, NY, which offers laboratory and other organizational capabilities to support nasal and injectable drug delivery systems.

This breakthrough therapy approval is an example of a Combination Product, and benefited from Aptar Pharma’s Services offering, a comprehensive portfolio of stage-specific packages designed to proactively address regulatory needs to accelerate approval.

“We are pleased that Aptar Pharma’s Bidose nasal delivery device has been approved by the FDA for this breakthrough therapy in the field of depression,” explained Gael Touya, President, Aptar Pharma. “This project marks close to a 10-year customer collaboration and once again demonstrates Aptar Pharma’s ability to develop and launch complex drug delivery systems worldwide.”

For more details, please download for our full Press Release.

March 18, 2019

Aptar Pharma to Exhibit Latest Injectable Developments at 2019 PD...

Aptar Pharma is pleased to be exhibiting at the 2019 PDA Annual Meeting, which takes place March 11-13, 2019 at the Marriott Marquis San Diego, CA.

This year at Aptar Pharma’s Booth No. 600, our experts will be showcasing the latest developments in our Premium product portfolio for elastomers, including Aptar Pharma’s PremiumCoat™.

Another highlight of our booth will be our industry award-winning Aptar Pharma QuickStart™ for Injectables solution – a sterile, Ready-To-Use (RTU) drug development offering designed specifically to accelerate the development time for start-ups and early stage development, R&D, biotechs and university research organizations. Recently launched, Aptar Pharma QuickStart™ for Injectables is available for online ordering here.

Visitors to our booth can also find out more about Aptar Pharma’s expanded manufacturing capacity in North America.

During 2019 PDA Annual Meeting, Aptar Pharma will present two posters at the Poster Sessions:

Migration Study to Evaluate the Impact of Steam vs. Gamma Irradiation in Ready-To-Use (RTU) Uncoated Stoppers and Fluorinated (ETFE) Film Coated Stoppers” will be presented by Michael J. Mayer, Senior Scientist from Next Breath, a specialty company of Aptar Pharma.

Establishing a Market Leading Answer to a Reduced Particulates Profile for Elastomeric Solution” will be presented by Arnaud Fournier, Senior Business Project Manager, Aptar Pharma.

Delegates at the event will have the opportunity to attend the Poster Sessions on both Tuesday, March 12 and Wednesday, March 13 between 10:00am and 10:45am.

With this year’s theme Solving Manufacturing and Supply Challenges for Current and Future Medicinal Products, the 2019 PDA Annual Meeting is the PDA’s flagship annual event, providing a learning and sharing venue for industry experts to gather the latest and most comprehensive information in the pharmaceutical manufacturing field.

Aptar Pharma is once again thrilled to be part of this event. To connect with Aptar Pharma and meet our team of experts, be sure to drop by our Booth No. 600. Register for the 2019 PDA Annual Meeting here.

March 6, 2019

Aptar Pharma’s Preservative-Free Multidose Dispenser Approved A...

Aptar Pharma is pleased to announce that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser has been approved for Santen’s prescription drug Taflotan®/Saflutan® for the reduction of elevated intraocular pressure (IOP) in open angle glaucoma and ocular hypertension in 26 countries in Europe.

This approval reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as an approved delivery system for eye disease treatment formulations without any preservatives.

Aptar Pharma is working closely with leading global ophthalmology specialist Santen Pharmaceutical Co., Ltd. to improve patient safety, achieve dosing accuracy and maintain product integrity.

A specialized global pharmaceutical company dedicated to the ophthalmology field, Santen is dedicated to the development and marketing of preservative-free drugs as part of its mission to contribute to the well-being of their patients, as well as society.

“We are delighted to launch preservative-free multi-dose formulations of these glaucoma therapies in Europe,” said Luis Iglesias, Corporate Officer and Head of EMEA, Santen. “By providing highly effective and well-tolerated, preservative-free medicines, with the option for multi-dose bottles, we hope to empower patients in their daily lives and improve the management of their condition.”

Aptar Pharma’s Ophthalmic Squeeze Dispenser system is the result of more than 10 years of development and experience in the delivery of preservative-free ophthalmic solutions. Patients and consumers in the U.S., Europe, Latin America and Asia have benefited from this technology since 2012, with more than 175 commercial references now available on the market (1).

“The proven and unrivalled microbiological safety, combined with a precise and reproducible drop ejection, allows pharmaceutical customers worldwide to enter into discussions with regulatory agencies such as the German BfArM with confidence,” said Matthias Birkhoff, VP Business Development, Aptar Pharma. Mr. Birkhoff also referred to the user-friendliness of the system, adding “The ergonomic, pocket-size design and the intuitiveness of a squeezable container with a low actuation force certainly contribute to the high levels of acceptance among patients and consumers worldwide.”

Please click here to download the full Press Release.

(1) Reference: Aptar Pharma White Paper available here.

 

February 26, 2019

Aptar Pharma QuickStart™ Injectables, a Drug Development Soluti...

Aptar Pharma is pleased to announce that their recently-launched QuickStart™ for Injectables has won Best Innovation in Packaging Material & Component category at the 2019 Pharmapack Awards in Paris, France.

QuickStart™ Injectables, which was showcased at the Innovation Gallery at Pharmapack this year, is a sterile, Ready-To-Use (RTU) drug development offering designed specifically to accelerate the development time for start-ups and early stage development, R&D, biotechs and university research organizations.

Launched at CPhI Worldwide in Madrid in October 2018, this highly-innovative injectable development package comes with gamma-sterilized stoppers and push-off caps from Aptar Pharma and EMA Pharmaceuticals respectively, and ETO sterilized vials from Schott, providing a one-stop solution allowing developers to focus on their science and chemistry.

QuickStart™ Injectables offers everything needed for the small-volume filling of high value formulations, including various sizes and configurations of vials, stoppers and caps, giving customers better quality, flexibility, convenience and speed. It also includes all of the quality and technical documentation required to verify the sterilization and compatibility (CCI) of components to proactively address regulators’ needs and accelerate approval.

Aptar Pharma also announced at Pharmapack 2019 that the award-winning QuickStart™ development package is now available for online purchase via the Aptar Pharma website utilizing a convenient, easy-to-use configurator, further simplifying access for research scientists and drug developers with a click of a button.

Accepting the award at Pharmapack 2019, Bas Van Buijtenen, President of the Aptar Pharma Injectables Division said, “We are delighted that QuickStart™ Injectables has won ‘Best Innovation in Packaging Material & Component’ at this year’s Pharmapack Awards. With QuickStart™ Injectables, we are enabling small scale sterile fills for innovative drug companies. Because we offer a small scale packaging solution identical to what will be used for large scale fills, these innovators gain reliability and time in their drug development pipeline”.

For more details and further information on QuickStart™ Injectables, please click here for the full Press Release.

February 7, 2019